Sex differences in the clearance of CYP3A4 substrates: Exploring possible reasons for the substrate dependency and lack of consensus

Current Drug Metabolism

Volumn 13, Issue 6, 2012, Pages 778-786

  Chetty, Manoranjenni ^a   Mattison, Donald ^b   Rostami Hodjegan, Amin ^a,c  

^a CERTARA UK LIMITED   (United Kingdom)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Benzodiazepines; Clearance differences; CYP3A4 substrates; Sex differences; Study power

Indexed keywords

ALPRAZOLAM; CLOZAPINE; CYTOCHROME P450 3A4; MIDAZOLAM; NIFEDIPINE; TRIAZOLAM; ZOLPIDEM;

ADULT; AGED; ARTICLE; ENZYME METABOLISM; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER METABOLISM; MALE; SEX DIFFERENCE;

ADULT; BENZODIAZEPINES; COMPUTER SIMULATION; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NIFEDIPINE; PYRIDINES; SEX CHARACTERISTICS;

EID: 84862590014     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012800840464     Document Type: Article

References (69)

1. Nicolas, J.M.; Espie, P.; Molimard, M. Gender and interindividual variability in pharmacokinetics. Drug Metab. Rev., 2009, 41(3), 408-421.
2. Soldin, O.P.; Mattison, D.R. Sex differences in pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet., 2009, 48(3), 143-157.
3. Bebawy, M.; Chetty, M. Gender differences in p-glycoprotein expression and function: effects on drug disposition and outcome. Curr. Drug Metab., 2009, 10(4), 322-328.
4. Waxman, D J.; Holloway, M.G. Sex differences in the expression of hepatic drug metabolizing enzymes. Mol. Pharmacol., 2009, 76(2), 215-228.
5. Bigos, K.L.; Pollock, B.G.; Stankevich, B.A.; Bies, R.R. Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: an updated review. Gend. Med., 2009, 6(4), 522-543.
6. Schwartz, J.B. The influence of sex on pharmacokinetics. Clin. Pharmacokinet., 2003, 42(2), 107-121.
7. Chen, M.L.; Lee, S.C.; Ng, M.J.; Schuirmann, D.J.; Lesko, L.J.; Williams, R.L. Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin. Pharmacol. Ther., 2000, 68(5), 510-521.
8. Meyer, M.C.; Straughn, A.B.; Mhatre, R.M.; Shah, V.P.; Chen, M.L.; Williams, R.L.; Lesko, L.J. Variability in the bioavailability of phenytoin capsules in males and females. Pharm.Res., 2001, 18(3), 394-397.
9. Cotreau, M.M.; von Moltke, L.L. Greenblatt, D.J. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin. Pharmacokinet., 2005, 44(1), 33-60.
10. Paine, M.F.; Hart, H.L.; Ludington, S.S.; Haining, R.L.; Rettie, A.E.; Zeldin, D.C. The human intestinal cytochrome P450 "pie". Drug Metab. Dispos., 2006, 34(5), 880-886.
11. Guengerich, F.P. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem. Res. Toxicol., 1990, 3(4), 363-371.
12. Schirmer, M.; Rosenberger, A.; Klein, K.; Kulle, B.; Toliat, M. R.; Nurnberg, P.; Zanger, U. M.; Wojnowski, L. Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. Pharmacogenomics, 2007, 8(5), 443-453.
13. Williams, J.A.; Johnson, K.; Paulauskis, J.; Cook, J. So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics. J. Clin. Pharmacol., 2006, 46(3), 258-264.
14. Rostami-Hodjegan, A.; Tucker, G.T. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev., 2007, 6(2), 140-148.
15. FDA. Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs. Federal Register Notice 58: 1993; pp. 39406-39416.
16. Jamei, M.; Marciniak, S.; Feng, K.; Barnett, A.; Tucker, G.; Rostami-Hodjegan, A. The Simcyp population-based ADME simulator. Exp. Opin. Drug Metab. Toxicol., 2009, 5(2), 211-223.
17. Greenblatt, D.J.; von Moltke, L.L. Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. J. Clin. Pharmacol., 2008, 48(11), 1350-1355.
18. Eiermann, B.; Engel, G.; Johansson, I.; Zanger, U.M.; Bertilsson, L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br. J. Clin. Pharmacol., 1997, 44(5), 439-446.
19. Ma, J.D.; Nafziger, A.N.; Rhodes, G.; Liu, S.; Bertino, J.S., Jr. Duration of pleconaril effect on cytochrome P450 3A activity in healthy adults using the oral biomarker midazolam. Drug Metab. Dispos., 2006, 34(5), 783-785.
20. Chung, E.; Nafziger, A.N.; Kazierad, D.J.; Bertino, J.S., Jr. Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin. Pharmacol. Ther. 2006, 79(4), 350-361.
21. Greenblatt, D.J.; Divoll, M.; Abernethy, D.R.; Moschitto, L.J.; Smith, R.B.; Shader, R.I. Reduced clearance of triazolam in old age: relation to antipyrine oxidizing capacity. Br. J. Clin. Pharmacol., 1983, 15(3), 303-309.
22. Kashuba, A.D.; Nafziger, A.N.; Kearns, G.L.; Leeder, J.S.; Gotschall, R.; Rocci, M.L., Jr.; Kulawy, R.W.; Beck, D.J.; Bertino, J.S., Jr. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin. Pharmacol. Ther., 1998, 64(3), 257-268.
23. Lawendv, N.M.; Holt, J.L.; Fullerton, J.; Nafziger, A.N.; Snyder, P.J.; Victory, J.; Bertino, J. S. Pharmacokinetics (PK) and pharmacodynamics (PD) of orally (PO) administered midazolam (MDZ) in the presence and absence of intravenous (IV) flumazenil (F) in healthy volunteers [abstract no. PI-52]. Clin. Pharmacol. Ther., 2005, 73(2), 15.
24. Lowry, J.A. Kearns, G.L.; Abdel-Rahman, S.M.; Nafziger, A.N.; Khan, I.S.; Kashuba, A.D.; Schuetz, E.G.; Bertino, J.S., Jr.; van den Anker, J.N.; Leeder, J.S. Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo. Clin. Pharmacol. Ther., 2003, 73(3), 209-222.
25. Rogers, J.F.; Morrison, A.L.; Nafziger, A.N.; Jones, C.L.; Rocci, M.L., Jr.; Bertino, J.S., Jr. Flumazenil reduces midazolam-induced cognitive impairment without altering pharmacokinetics. Clin. Pharmacol. Ther., 2002, 72(6), 711-717.
26. Tsunoda, S.M.; Velez, R.L.; von Moltke, L.L.; Greenblatt, D.J. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin. Pharmacol. Ther., 1999, 66(5), 461-471.
27. Thummel, K.E.; O'Shea, D.; Paine, M.F.; Shen, D.D.; Kunze, K.L.; Perkins, J.D.; Wilkinson, G.R. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther., 1996, 59(5), 491-502.
28. Greenblatt, D.J.; Abernethy, D.R.; Locniskar, A.; Harmatz, J.S.; Limjuco, R.A.; Shader, R.I. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology, 1984, 61(1), 27-35.
29. Gorski, J.C.; Jones, D.R.; Haehner-Daniels, B.D.; Hamman, M.A.; O'Mara, E.M., Jr.; Hall, S. D. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin. Pharmacol. Ther., 1998, 64(2), 133-143.
30. Raemsch, K.D.; Sommer, J. Pharmacokinetics and metabolism of nifedipine. Hypertension, 1983, 5(4 Pt 2), II18-24.
31. Ahsan, C.H.; Renwick, A.G.; Macklin, B.; Challenor, V.F.; Waller, D.G.; George, C.F. Ethnic differences in the pharmacokinetics of oral nifedipine. Br. J. Clin. Pharmacol., 1991, 31(4), 399-403.
32. Imai, Y.; Abe, K.; Sasaki, S.; Nihei, M.; Sekino, H.; Yoshinaga, K. Pharmacokinetics and pharmacodynamics of conventional and slow release forms of nifedipine in essential hypertensive patients. Tohoku J. Exp. Med., 1986, 148(4), 421-438.
33. Renwick, A.G.; Robertson, D.R.; Macklin, B.; Challenor, V.; Waller, D.G.; George, C.F. The pharmacokinetics of oral nifedipine-a population study. Br. J. Clin. Pharmacol., 1988, 25(6), 701-708.
34. Robertson, D.R.; Waller, D.G.; Renwick, A.G.; George, C.F. Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. Br. J. Clin. Pharmacol., 1988, 25(3), 297-305.
35. Chung, M.; Reitberg, D.P.; Gaffney, M.; Singleton, W. Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine. Am. J. Med., 1987, 83(6B), 10-14.
36. Krecic-Shepard, M.E.; Park, K.; Barnas, C.; Slimko, J.; Kerwin, D.R.; Schwartz, J.B. Race and sex influence clearance of nifedipine: results of a population study. Clin. Pharmacol. Ther., 2000, 68 (2), 130-42.
37. Greenblatt, D.J.; Divoll, M.; Abernethy, D.R.; Moschitto, L.J.; Smith, R.B.; Shader, R.I. Alprazolam kinetics in the elderly. Relation to antipyrine disposition. Arch. Gen. Psychiatr., 1983, 40(3), 287-90.
38. Smith, R.B.; Gwilt, P.R.; Wright, C.E., 3rd. Single-and multiple-dose pharmacokinetics of oral alprazolam in healthy smoking and nonsmoking men. Clin. Pharm. 1983, 2(2), 139-143.
39. Stoehr, G.P.; Kroboth, P.D.; Juhl, R.P.; Wender, D.B.; Phillips, J.P.; Smith, R.B. Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics. Clin. Pharmacol. Ther., 1984, 36(5), 683-690.
40. Greenblatt, D.J.; Harmatz, J.S.; Dorsey, C.; Shader, R.I. Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo. Clin. Pharmacol. Ther., 1988, 44(3), 326-334.
41. Ciraulo, D.A.; Barnhill, J.G.; Boxenbaum, H.G.; Greenblatt, D.J.; Smith, R.B. Pharmacokinetics and clinical effects of alprazolam following single and multiple oral doses in patients with panic disorder. J. Clin. Pharmacol., 1986, 26(4), 292-298.
42. Kristjansson, F.; Thorsteinsson, S.B. Disposition of alprazolam in human volunteers. Differences between genders. Acta Pharm. Nord., 1991, 3(4), 249-250.
43. Kroboth, P.D.; McAuley, J.W.; Smith, R.B. Alprazolam in the elderly: pharmacokinetics and pharmacodynamics during multiple dosing. Psychopharmacology, 1990, 100(4), 477-484.
44. Greenblatt, D.J.; Harmatz, J.S.; von Moltke, L.L.; Wright, C.E.; Durol, A.L.; Harrel-Joseph, L.M.; Shader, R.I. Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. J. Pharmacol. Exp.Ther., 2000, 293(2), 435-443.
45. Greenblatt, D.J.; Harmatz, J.S.; von Moltke, L.L.; Wright, C.E.; Shader, R.I. Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clin. Pharmacol. Ther., 2004, 76(5), 467-479.
46. Smith, R.B.; Divoll, M.; Gillespie, W.R.; Greenblatt, D.J. Effect of subject age and gender on the pharmacokinetics of oral triazolam and temazepam. J. Clin. Psychopharmacol., 1983, 3(3), 172-176.
47. Greenblatt, D.J.; Harmatz, J.S.; Gouthro, T.A.; Locke, J.; Shader, R.I. Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies. Clin. Pharmacol. Ther., 1994, 56(1), 100-111.
48. Greenblatt, D.J.; Harmatz, J.S.; von Moltke, L.L.; Ehrenberg, B.L.; Harrel, L.; Corbett, K.; Counihan, M.; Graf, J.A.; Darwish, M.; Mertzanis, P.; Martin, P.T.; Cevallos, W.H.; Shader, R.I. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin. Pharmacol. Ther., 1998, 64(5), 553-561.
49. Salva, P.; Costa, J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clin. Pharmacokinet., 1995, 29(3), 142-153.
50. Olubodun, J.O.; Ochs, H.R.; von Moltke, L.L.; Roubenoff, R.; Hesse, L.M.; Harmatz, J.S.; Shader, R.I.; Greenblatt, D.J. Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. Br. J. Clin. Pharmacol., 2003, 56(3), 297-304.
51. Olubodun, J.O.; Ochs, H.R.; Truten, V.; Klein, A.; von Moltke, L.L.; Harmatz, J.S.; Shader, R.I.; Greenblatt, D.J. Zolpidem pharmacokinetic properties in young females: influence of smoking and oral contraceptive use. J. Clin. Pharmacol., 2002, 42(10), 1142-1146.
52. Howgate, E.M.; Rowland Yeo, K.; Proctor, N.J.; Tucker, G.T.; Rostami-Hodjegan, A. Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica, 2006, 36(6), 473-497.
53. Rostami-Hodjegan, A.; Tucker, G.T. The effects of portal shunts on intestinal cytochrome P450 3A activity. Hepatology, 2002, 35(6), 1549-1550; author reply 1550-1551.
54. Yang, J.; Jamei, M.; Rowland-Yeo, K.; Tucker, G.T.; Rostami-Hodjegan, A. Prediction of intestinal first-pass drug metabolism. Curr. Drug Metab., 2007, 8(7), 676-684.
55. Gertz, M.; Harrison, A.; Houston, J.B.; Galetin, A. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab. Dispos., 2010, 38(7), 1147-1158.
56. Jamei, M.; Dickinson, G.L.; Rostami-Hodjegan, A. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab. Pharmacokinet., 2009, 24(1), 53-75.
57. Rowland Yeo, K.; Jamei, M.; Yang, J.; Tucker, G.T.; Rostami-Hodjegan, A. Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut-the effect of diltiazem on the time-course of exposure to triazolam. Eur. J. Pharm. Sci., 2010, 39(5), 298-309.
58. Barter, Z.E.; Perrett, H.F.; Rowland-Yeo, K.; Allorge, D.; Lennard, M.S.; Rostami-Hodjegan, A. Determination of a quantitative relationship between hepatic CYP3A5*1*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations. Biopharm. Drug Dispos., 2010, 31(8-9), 516-532.
59. Rowland-Yeo, K.; Rostami-Hodjegan, A.; Tucker, G.T. Abundance of cytochromes P450 in human liver: a meta-analysis. In: BPS Winter Meeting; 2003, December 16-18; GKT School of Biomedical Sciences, Guy's Campus, King's College London. Br. J. Clin. Pharmacol., 2004, 57, 687-688.
60. Kuehl, P.; Zhang, J.; Lin, Y.; Lamba, J.; Assem, M.; Schuetz, J.; Watkins, P.B.; Daly, A.; Wrighton, S.A.; Hall, S.D.; Maurel, P.; Relling, M.; Brimer, C.; Yasuda, K.; Venkataramanan, R.; Strom, S.; Thummel, K.; Boguski, M.S.; Schuetz, E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet., 2001, 27(4), 383-391.
61. Hustert, E.; Haberl, M.; Burk, O.; Wolbold, R.; He, Y.Q.; Klein, K.; Nuessler, A.C.; Neuhaus, P.; Klattig, J.; Eiselt, R.; Koch, I.; Zibat, A.; Brockmoller, J.; Halpert, J.R.; Zanger, U.M.; Wojnowski, L. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics, 2001, 11(9), 773-779.
62. Chen, M.; Ma, L.; Drusano, G.L.; Bertino, J.S., Jr.; Nafziger, A.N. Sex differences in CYP3A activity using intravenous and oral midazolam. Clin. Pharmacol. Ther., 2006, 80(5), 531-538.
63. Polasek, T.M.; Miners, J.O. Response to "Zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A: sex as a differentiating factor". Eur. J. Clin. Pharmacol., 2010, 66(9), 957-958.
64. Perucca, J.; Bouby, N.; Valeix, P.; Bankir, L. Sex difference in urine concentration across differing ages, sodium intake, and level of kidney disease. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2007, 292(2), R700-705.
65. Hancock, M.L., 2nd; Bichet, D.G.; Eckert, G.J.; Bankir, L.; Wagner, M.A.; Pratt, J.H. Race, sex, and the regulation of urine osmolality: observations made during water deprivation. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2010, 299(3), R977-980.
66. Sartori-Valinotti, J.C.; Iliescu, R.; Yanes, L.L.; Dorsett-Martin, W.; Reckelhoff, J.F. Sex differences in the pressor response to angiotensin II when the endogenous renin-angiotensin system is blocked. Hypertension, 2008, 5(4), 1170-1176.
67. Miller, J.A.; Anacta, L.A.; Cattran, D.C. Impact of gender on the renal response to angiotensin II. Kidney Int., 1999, 55(1), 278-285.
68. Whitley, H.P.; Lindsey, W. Sex-based differences in drug activity. Am. Fam. Physician., 2009, 80(11), 1254-1258.
69. Clark, R. Sex differences in antiretroviral therapy-associated intolerance and adverse events. Drug Saf., 2005, 28(12), 1075-1083.